No US Filing Until 2026? Aurobindo’s CuraTeQ Inks Ustekinumab Deal
Arrangement With US-Based BioFactura Provides For Broad Global Rights
With J&J’s blockbuster Stelara treatment for autoimmune diseases scheduled to fall to biosimilar competition in the coming years, Aurobindo’s biosimilars business has stepped up to get a piece of the action, striking a deal with BioFactura.
